$ATRA
Atara Biotherapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022018253 Filed on May 05, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $7.314M $3.550M
YoY Change 106.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $20.57M $17.74M
YoY Change 15.96% 4.11%
% of Gross Profit
Research & Development $74.96M $64.06M
YoY Change 17.02% 11.1%
% of Gross Profit
Depreciation & Amortization $1.591M $2.220M
YoY Change -28.33% 13.85%
% of Gross Profit
Operating Expenses $95.53M $81.80M
YoY Change 16.79% 9.51%
Operating Profit -$88.22M
YoY Change
Interest Expense $115.0K -$90.00K
YoY Change -227.78% -107.56%
% of Operating Profit
Other Income/Expense, Net $115.0K -$90.00K
YoY Change -227.78% -107.58%
Pretax Income -$88.11M -$78.34M
YoY Change 12.46% 6.57%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$88.11M -$78.34M
YoY Change 12.47% 6.57%
Net Earnings / Revenue -1204.61% -2206.62%
Basic Earnings Per Share -$0.87
Diluted Earnings Per Share -$874.7K -$856.5K
COMMON SHARES
Basic Shares Outstanding 100.7M
Diluted Shares Outstanding 100.7M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $301.8M $435.2M
YoY Change -30.65% 102.8%
Cash & Equivalents $101.7M $151.1M
Short-Term Investments $200.1M $284.1M
Other Short-Term Assets $11.91M $19.50M
YoY Change -38.92% 33.56%
Inventory
Prepaid Expenses
Receivables $668.0K $9.600M
Other Receivables $0.00 $0.00
Total Short-Term Assets $314.4M $464.3M
YoY Change -32.29% 102.58%
LONG-TERM ASSETS
Property, Plant & Equipment $9.109M $51.47M
YoY Change -82.3% -5.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $54.85M $729.0K
YoY Change 7423.87% -66.86%
Total Long-Term Assets $82.89M $65.33M
YoY Change 26.88% -7.07%
TOTAL ASSETS
Total Short-Term Assets $314.4M $464.3M
Total Long-Term Assets $82.89M $65.33M
Total Assets $397.3M $529.6M
YoY Change -24.99% 76.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.95M $17.36M
YoY Change -31.17% 114.26%
Accrued Expenses $30.37M $23.40M
YoY Change 29.79% 33.71%
Deferred Revenue $35.50M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $101.6M $84.20M
YoY Change 20.62% 167.3%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $616.0K $2.026M
YoY Change -69.6% -86.67%
Total Long-Term Liabilities $616.0K $2.026M
YoY Change -69.6% -86.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $101.6M $84.20M
Total Long-Term Liabilities $616.0K $2.026M
Total Liabilities $102.2M $130.6M
YoY Change -21.76% 179.66%
SHAREHOLDERS EQUITY
Retained Earnings -$1.203B
YoY Change 34.93%
Common Stock $1.602B
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $224.3M $399.0M
YoY Change
Total Liabilities & Shareholders Equity $397.3M $529.6M
YoY Change -24.99% 76.84%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$88.11M -$78.34M
YoY Change 12.47% 6.57%
Depreciation, Depletion And Amortization $1.591M $2.220M
YoY Change -28.33% 13.85%
Cash From Operating Activities -$84.53M -$65.70M
YoY Change 28.66% -2.01%
INVESTING ACTIVITIES
Capital Expenditures $2.605M $2.197M
YoY Change 18.57% 64.82%
Acquisitions
YoY Change
Other Investing Activities $62.82M $15.70M
YoY Change 300.13% -61.05%
Cash From Investing Activities $60.22M $13.50M
YoY Change 346.07% -65.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $20.54M $2.457M
YoY Change 735.94% -89.88%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.85M 2.892M
YoY Change 586.41% -87.93%
NET CHANGE
Cash From Operating Activities -84.53M -65.70M
Cash From Investing Activities 60.22M 13.50M
Cash From Financing Activities 19.85M 2.892M
Net Change In Cash -4.463M -49.31M
YoY Change -90.95% 1098.52%
FREE CASH FLOW
Cash From Operating Activities -$84.53M -$65.70M
Capital Expenditures $2.605M $2.197M
Free Cash Flow -$87.13M -$67.90M
YoY Change 28.34% -0.7%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2012-08-01
CY2022Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
190000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
51429000
CY2021Q4 us-gaap Assets
Assets
468127000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17368000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
25150000
CY2021Q4 atra Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
13451000
CY2022Q1 us-gaap Deferred Income Current
DeferredIncomeCurrent
50943000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
40760000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8051000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9057000
CY2022Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
252000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
101562000
CY2022Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45000000
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
55708000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
17453000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
616000
CY2022Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
8333000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
14335000
CY2022Q1 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
7314000
CY2021Q1 atra License And Collaboration Revenue
LicenseAndCollaborationRevenue
3552000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64059000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-88220000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
115000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-90000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-78335000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
279614000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
616000
CY2022Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
96000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14335000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-88105000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1524000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
462339000
CY2021Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
1231000
CY2021Q1 atra Issuance Of Common Stock Pursuant To Employee Stock Awards Value
IssuanceOfCommonStockPursuantToEmployeeStockAwardsValue
1749000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12268000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-78335000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-135000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
399037000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-88105000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-78335000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12268000
CY2022Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-498000
CY2021Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-360000
CY2022Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
627000
CY2021Q1 atra Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
373000
CY2021Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6058000
CY2022Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-645000
CY2021Q1 atra Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-406000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
98000
CY2021Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84529000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-65698000
CY2022Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
26427000
CY2022Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
89247000
CY2021Q1 us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
109751000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2605000
CY2022Q1 us-gaap Accretion Expense
AccretionExpense
7000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-318000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8360000
CY2022Q1 atra Increase Decrease In Accrued Research And Development
IncreaseDecreaseInAccruedResearchAndDevelopment
539000
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-570000
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1510000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-525000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2197000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
60215000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13499000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20539000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2457000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
96000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1749000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
616000
CY2021Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1231000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
64000
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
66000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-104000
CY2021Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-17000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19851000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2892000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4463000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-49307000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107478000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201798000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103015000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
152491000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1188000
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1245000
CY2022Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
0
CY2021Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To Underwritten Public Offering
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToUnderwrittenPublicOffering
176000
CY2022Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
23000
CY2021Q1 atra Non Cash Investing And Financing Activities Accrued Costs Related To At The Market Facility
NonCashInvestingAndFinancingActivitiesAccruedCostsRelatedToAtTheMarketFacility
75000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
5000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
10000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
14000
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
8000
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
100000000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1400000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions, and judgments that affect the amounts reported in the financial statements and accompanying notes. Significant estimates relied upon in preparing these financial statements include estimates related to revenue recognition, clinical study and other accruals, stock-based compensation expense and income taxes. Actual results could differ materially from those estimates. </p>
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19010181
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14096130
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
243102000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
242264000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
278457000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
278354000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
58746000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
57692000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
91383000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
91118000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
301848000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
299956000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
369840000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
369472000
CY2022Q1 us-gaap Interest Receivable
InterestReceivable
600000
CY2021Q3 us-gaap Interest Receivable
InterestReceivable
800000
CY2022Q1 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2021Q3 atra Write Off Of Accrued Interest Receivable
WriteOffOfAccruedInterestReceivable
0
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
1300000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
107478000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101669000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106084000
CY2022Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
146000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
194000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1200000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103015000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19360000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
82518000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10251000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28738000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9109000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53780000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1600000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2200000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
100000000
CY2022Q1 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
0
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Prepaid And Other Assets Current
DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
190000
CY2022Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
190000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Noncurrent
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
44791000
CY2022Q1 atra Disposal Group Including Discontinued Operation Operating Lease Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationOperatingLeaseAssetsNoncurrent
6599000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Other Noncurrent Assets
DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
39000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Assets Noncurrent
DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent
51429000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Other Current Liabilities
DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
252000
CY2022Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
252000
CY2022Q1 atra Disposal Group Including Discontinued Operation Operating Lease Liabilities Long Term Liabilities
DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilitiesLongTermLiabilities
7373000
CY2022Q1 us-gaap Disposal Group Including Discontinued Operation Other Noncurrent Liabilities
DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
960000
CY2022Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Noncurrent
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
8333000
CY2022Q1 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2021Q4 atra Contractual Obligations Due To Licensors
ContractualObligationsDueToLicensors
0
CY2022Q1 atra Recorded Unconditional Service Obligations Due Within One Year
RecordedUnconditionalServiceObligationsDueWithinOneYear
25273
CY2022Q1 atra Recorded Unconditional Service Obligation Due In Second Year
RecordedUnconditionalServiceObligationDueInSecondYear
33275
CY2022Q1 atra Recorded Unconditional Service Obligations Due Within Third Year
RecordedUnconditionalServiceObligationsDueWithinThirdYear
28179
CY2022Q1 atra Recorded Unconditional Service Obligations Due In Fourth Year
RecordedUnconditionalServiceObligationsDueInFourthYear
27645
CY2022Q1 atra Recorded Unconditional Service Obligations Due In Fifth Year
RecordedUnconditionalServiceObligationsDueInFifthYear
24189
CY2022Q1 atra Recorded Unconditional Service Obligations Due After Fifth Year
RecordedUnconditionalServiceObligationsDueAfterFifthYear
6229
CY2022Q1 atra Recorded Unconditional Service Obligation
RecordedUnconditionalServiceObligation
144790
CY2022Q1 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2021Q4 atra Accrued Termination Charges
AccruedTerminationCharges
0
CY2022Q1 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2021Q4 atra Liabilities Related To Indemnification Agreements
LiabilitiesRelatedToIndemnificationAgreements
0
CY2022Q1 us-gaap Capital Units Authorized
CapitalUnitsAuthorized
520000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Terms Of Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
the exercise price of an option granted to a 10% shareholder cannot be less than 110% of the estimated fair value of the shares on the date of grant. Options granted generally vest over four years and expire in seven to ten years.
CY2022Q1 atra Shareholder Ownership Percent
ShareholderOwnershipPercent
0.10
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
25371232
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14335000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12268000

Files In Submission

Name View Source Status
0001564590-22-018253-index-headers.html Edgar Link pending
0001564590-22-018253-index.html Edgar Link pending
0001564590-22-018253.txt Edgar Link pending
0001564590-22-018253-xbrl.zip Edgar Link pending
atra-10q_20220331.htm Edgar Link pending
atra-10q_20220331_htm.xml Edgar Link completed
atra-20220331.xsd Edgar Link pending
atra-20220331_cal.xml Edgar Link unprocessable
atra-20220331_def.xml Edgar Link unprocessable
atra-20220331_lab.xml Edgar Link unprocessable
atra-20220331_pre.xml Edgar Link unprocessable
atra-ex101_46.htm Edgar Link pending
atra-ex311_7.htm Edgar Link pending
atra-ex312_6.htm Edgar Link pending
atra-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g0stvaspaqn2000001.jpg Edgar Link pending
g0stvaspaqn2000002.jpg Edgar Link pending
g0stvaspaqn2000003.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending